Results 161 to 170 of about 30,178 (280)

A photoimmune synergizing RNA interference technology for highly effective antitumor treatment

Smart Molecules, EarlyView.
We developed a red‐light‐activated small‐molecule photosensitizer FNBS, which enables simultaneous photodynamic immunotherapy and RNA interference. FNBS can induce pyroptosis, immunogenic cell death and RNA degradation, avoiding the carrier‐dependent delivery drawbacks of conventional RNAi therapy, converting cold tumors into hot tumors and ...
Xiang Xia, Bingbing Wu, Xueze Zhao, Wen Sun, Jianjun Du, Jiangli Fan, Xiaojun Peng   +6 more
wiley   +1 more source

Endovascular stem cell therapy reconfigures post-stroke ER dynamics via GRP78/Atlastin/CHOP axis. [PDF]

Mol Brain
Kumari A, Yadav J, Godse P, Karmarkar G, Dubey A, More A, Saha C, Ghosh B, Datta A, Barik A, Borah A, Yavagal DR, Bhattacharya P.   +12 more
europepmc   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Rituximab-Conjugated DART Nanoformulation for CD20-Targeted Drug Delivery in Non-Hodgkin Lymphoma. [PDF]

Int J Nanomedicine
Mahmud MM, Kong B, Lee D, Pinzon Burgos EF, Heredia A, Suk JS, Kim AJ.   +6 more
europepmc   +1 more source

Large‐Scale Applications of Plasma Technologies: Progresses and Challenges

High Voltage, EarlyView.
ABSTRACT Plasma technologies convert electrical power into energetic electrons, ions, reactive species, radiation and heat, thereby breaking through the bottleneck of purely thermal or chemical routes and bringing impressive changes to our world. This roadmap reviews the progress and challenges of plasma technologies from a large‐scale and application ...
Pankaj Attri, Liuyang Bai, Dmitry Batomunkuev, Xueke Che, Guoxing Chen, Zhitong Chen, Wei Cui, Liguang Dou, Zhi Fang, Yangyang Fu, Fausto Gallucci, Yiming Guo, Bangdou Huang, Yinghong Li, Sirui Li, Hua Liang, Liangliang Lin, Dingxin Liu, Xiangyang Liu, Xinpei Lu, Ruonan Ma, Lanlan Nie, Guanghui Niu, Yuge Ouyang, Tao Shao, Jing Sun, Yong Tang, Xin Tu, Sergey P. Vashchenko, Hang Wang, Xianjie Wang, Anke Weidenkaff, Yun Wu, Haohan Xie, Shaojun Xu, Zongxian Yang, Fangli Yuan, Cheng Zhang, Hao Zhang, Jishen Zhang, Shuai Zhang, Yejian Zhang, Zhe Zhang, Zhibo Zhang, Peng Zhao, Shicheng Zhao, Linlin Zhong, Renwu Zhou, Zhenhua Zhou, Xi Zhu, Yifei Zhu, Haohua Zong   +51 more
wiley   +1 more source

Two decades of immunogenic cell death research: a bibliometric analysis of the 100 most cited publications. [PDF]

Front Oncol
Guan L, Guo L, Liu Y, Bao S, Chen M, Luo J, Zhang H, Yang S.   +7 more
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Single-cell transcriptomic characterization of the immunosuppressive tumor immune microenvironment in hepatocellular carcinoma: implications for SBRT-based radio-immunotherapy. [PDF]

Front Cell Dev Biol
Zhang X, Ma X, Chen S, Mo Y, Lu X, Xie Y, Liu X, Hou E.   +7 more
europepmc   +1 more source

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

British Journal of Haematology, EarlyView.
Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, on behalf of the Spanish MPN Group (GEMFIN)   +35 more
wiley   +1 more source

Mutational landscape of classical myeloproliferative neoplasms in the Western Cape Province, South Africa. [PDF]

Afr J Lab Med
Dicks MJ, Nell EM, Swanepoel C, Abdullah I, Chapanduka ZC.   +4 more
europepmc   +1 more source